Identification of Pathogenic Bacteria of Diabetes Foot Ulcer

NCT ID: NCT06777810

Last Updated: 2025-01-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-31

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to design and develop a gene chip for detecting pathogenic bacteria in diabetic foot infection wounds. This innovative gene chip technology enables rapid and accurate identification of pathogens at the site of infection by detecting the 16SrDNA sequence of pathogenic bacteria.

Diabetic foot infection is a common serious complication in diabetic patients, often accompanied by complex pathogenic bacteria population, and due to the variety of infection types, traditional pathogen detection methods are time-consuming and low accuracy, patients may miss the best treatment opportunity. Now commonly used genetic identification of pathogenic bacteria often find a variety of bacteria, resulting in the actual pathogenic bacteria difficult to judge.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Based on the principle of 16SrDNA detection, this study developed an efficient and convenient gene chip, which can accurately identify and quantitatively analyze different types of pathogenic bacteria at the molecular level. Through this technology, it can significantly improve the diagnostic efficiency and accuracy of diabetic foot infection, provide patients with more timely treatment, reduce the risk of complications caused by infection, and improve the quality of life of patients.

Objective:

1. Development of efficient gene chip: Design a gene chip that can rapidly detect pathogenic bacteria in diabetic foot infection wounds. By detecting the 16SrDNA sequence, the chip can identify a variety of pathogenic bacteria and provide accurate data support for clinical diagnosis
2. Evaluate the difference in detection time between gene-chip detection technology and traditional schemes: traditional bacterial culture and identification methods usually take several days, but this study aims to shorten the detection time (i.e. the time from taking wound samples to getting pathogenic bacteria detection results) to several hours through gene-chip technology, so as to improve the diagnostic efficiency and obtain pathogenic bacteria information in time
3. Compare the sensitivity and specificity of gene chip and traditional methods (such as bacterial culture) in detecting pathogenic bacteria, and then obtain the changes in the diagnostic accuracy of gene chip technology: The Sensitivity, Specificity, positive predictive value (PPV), negative predictive value (NPV) and other key diagnostic indicators of the pathogen were tested for specificity of diabetic foot infection, and the diagnostic accuracy of specificity was verified by comparing with traditional bacterial specificity Methods:This study is a scientific research project carried out in the laboratory. Through consulting the common bacterial strains cultured by diabetic foot infection in our hospital, the probe is made by adding anaerobic bacterial strains according to the literature. Informed consent was signed, about 60 subjects were recruited according to inclusion and exclusion criteria, and more than three specimens were collected for each subject. One was used to analyze pathogenic bacteria by conventional bacterial culture method; One pathogen was sequenced using conventional 16SrDNA; A gene chip analysis, using quantitative chip technology, to determine the content of each bacteria, with the highest content of bacteria reference as a pathogen. The sequencing result of bacterial content detected by bacterial 16SrDNA chip, the highest content, should be consistent with the conventional bacterial culture results.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Disease Diabetic Foot Ulcer Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The infected wound of the patient's foot ulcer was collected

The infected wound of the patient's foot ulcer was collected

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years old
2. Gender: males and females
3. Patients diagnosed with diabetic foot infection with an infected wound
4. It can provide sufficient infected wound samples (≥5mm³ infected wound tissue samples or ≥100μL infected wound secretions) and can be used for detection and analysis of gene chips
5. No history of antibiotic therapy prior to sampling (within 4 weeks) or known failure to respond to antibiotic therapy (failure to respond to ≥2 antibiotics)
6. Fully understand the nature, significance, possible benefits, possible inconveniences or potential risks of this research; Understand the study procedure, participate voluntarily and be willing to complete the entire study process, and sign the informed consent

Exclusion Criteria

1. Patients with undiagnosed diabetic foot infection
2. Patients who had received antibiotics within 4 weeks prior to sampling
3. Complicated with serious systemic disease (e.g., malignant tumor, severe cardiopulmonary insufficiency, etc.)
4. Pregnant or lactating women
5. Cognitive impairment or inability to cooperate with the research process
6. History of allergies or allergies to materials related to the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shanghai Jiao Tong University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wang Weiqing

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Clinical Medical Research Center for Metabolic Diseases (Shanghai)

Shanghai, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Weiqing Wang, MD, PHD

Role: CONTACT

008621-64370045

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Weiqing Wang, Professor

Role: primary

008621-64370045

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CCEMD-20241002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Chemical Debridement and Leg Ulcers
NCT06652360 RECRUITING NA